{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:53:26Z","timestamp":1788314006611,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05775-z","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T04:01:21Z","timestamp":1714017681000},"page":"2993-3004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Daratumumab and venetoclax combined with CAGE for late R\/R T-ALL\/LBL patients: Single-arm, open-label, phase I study"],"prefix":"10.1007","volume":"103","author":[{"given":"Hui","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoai","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"5775_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951","journal-title":"Blood"},{"key":"5775_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mpo.2950200204","volume":"20","author":"C Patte","year":"1992","unstructured":"Patte C, Kalifa C, Flamant F, Hartmann O, Brugi\u00e8res L et al (1992) Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 20:105\u2013113","journal-title":"Med Pediatr Oncol"},{"key":"5775_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","volume":"16","author":"TG Gross","year":"2010","unstructured":"Gross TG, Hale GA, He W, Camitta BM, Sanders JE et al (2010) Hematopoietic stem cell transplantation for refractory or recurrent non-hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transpl 16:223\u2013230","journal-title":"Biol Blood Marrow Transpl"},{"key":"5775_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/pbc.21941","volume":"52","author":"T Mitsui","year":"2009","unstructured":"Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M (2009) Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer 52:591\u2013595","journal-title":"Pediatr Blood Cancer"},{"key":"5775_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood 109:944\u2013950","journal-title":"Blood"},{"key":"5775_CR6","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z et al (2021) Donor-derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: first-in-Human, phase I Trial. J Clin Oncol 39:3340\u20133351","journal-title":"J Clin Oncol"},{"key":"5775_CR7","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X et al (2022) Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood 140:321\u2013334","journal-title":"Blood"},{"key":"5775_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s00277-005-1090-9","volume":"84","author":"G Specchia","year":"2005","unstructured":"Specchia G, Pastore D, Carluccio P, Liso A, Mestice A et al (2005) FLAG-IDA in the treatment of refractory\/relapsed adult acute lymphoblastic leukemia. Ann Hematol 84:792\u2013795","journal-title":"Ann Hematol"},{"key":"5775_CR9","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","volume":"118","author":"N Hijiya","year":"2011","unstructured":"Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG et al (2011) Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 118:6043\u20136049","journal-title":"Blood"},{"key":"5775_CR10","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","volume":"23","author":"SL Berg","year":"2005","unstructured":"Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A et al (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group. J Clin Oncol 23:3376\u20133382","journal-title":"J Clin Oncol"},{"key":"5775_CR11","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","volume":"118","author":"N G\u00f6kbuget","year":"2011","unstructured":"G\u00f6kbuget N, Basara N, Baurmann H, Beck J, Br\u00fcggemann M et al (2011) High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation. Blood 118:3504\u20133511","journal-title":"Blood"},{"key":"5775_CR12","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1002\/cam4.3079","volume":"9","author":"JJ Qian","year":"2020","unstructured":"Qian JJ, Hu X, Wang Y, Zhang Y, Du J et al (2020) CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: a retrospective, multicenter, cohort study. Cancer Med 9:5327\u20135334","journal-title":"Cancer Med"},{"key":"5775_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ajh.21066","volume":"83","author":"SL Xue","year":"2008","unstructured":"Xue SL, Wu DP, Sun AN, Tang XW (2008) CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Am J Hematol 83:167\u2013170","journal-title":"Am J Hematol"},{"key":"5775_CR14","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/bjh.16960","volume":"191","author":"M Cerrano","year":"2020","unstructured":"Cerrano M, Castella B, Lia G, Olivi M, Faraci DG et al (2020) Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia. Br J Haematol 191:e28\u2013e32","journal-title":"Br J Haematol"},{"key":"5775_CR15","doi-asserted-by":"publisher","first-page":"e28829","DOI":"10.1002\/pbc.28829","volume":"68","author":"SD Ruhayel","year":"2021","unstructured":"Ruhayel SD, Valvi S (2021) Daratumumab in T-cell acute lymphoblastic leukaemia: a case report and review of the literature. Pediatr Blood Cancer 68:e28829","journal-title":"Pediatr Blood Cancer"},{"key":"5775_CR16","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/bjh.16154","volume":"187","author":"S Mirgh","year":"2019","unstructured":"Mirgh S, Ahmed R, Agrawal N, Khushoo V, Garg A et al (2019) Will Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol 187:e33\u2013e5","journal-title":"Br J Haematol"},{"key":"5775_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317","journal-title":"Blood"},{"key":"5775_CR18","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/ccr3.3041","volume":"8","author":"E Zappone","year":"2020","unstructured":"Zappone E, Cencini E, Defina M, Sicuranza A, Gozzetti A et al (2020) Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep 8:2000\u20132002","journal-title":"Clin Case Rep"},{"key":"5775_CR19","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1097\/HS9.0000000000000379","volume":"4","author":"A McEwan","year":"2020","unstructured":"McEwan A, Pitiyarachchi O, Viiala N (2020) Relapsed\/Refractory ETP-ALL successfully treated with Venetoclax and Nelarabine as a bridge to allogeneic stem cell transplant. Hemasphere 4:e379","journal-title":"Hemasphere"},{"key":"5775_CR20","doi-asserted-by":"crossref","unstructured":"La Starza R, Camb\u00f2 B, Pierini A, Bornhauser B, Montanaro A et al (2019) Venetoclax and Bortezomib in Relapsed\/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol 3","DOI":"10.1200\/PO.19.00172"},{"key":"5775_CR21","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Version 1.2022 Acute Lymphoblastic Leukemia. (2022) https:\/\/www.nccn.org"},{"key":"5775_CR22","unstructured":"U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (2017) Common Terminology Criteria for Adverse EVents (CTCAE)Version 5.0. CI Cancer Therapy Evaluation Program (CTEP). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5 Accessed March 29, 2021"},{"key":"5775_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1182\/hematology.2022000337","volume":"2022","author":"KM O\u2019Dwyer","year":"2022","unstructured":"O\u2019Dwyer KM (2022) Optimal approach to T-cell ALL. Hematol Am Soc Hematol Educ Program 2022:197\u2013205","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"5775_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40267-016-0346-x","volume":"32","author":"K McKeage","year":"2016","unstructured":"McKeage K, Lyseng-Williamson KA (2016) Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU. Drugs Therapy Perspect 32:463\u2013469","journal-title":"Drugs Therapy Perspect"},{"key":"5775_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM et al (2018) Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 131:995\u2013999","journal-title":"Blood"},{"key":"5775_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/bjh.14310","volume":"180","author":"AE Bras","year":"2018","unstructured":"Bras AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, Te Marvelde JG et al (2018) CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. Br J Haematol 180:292\u2013296","journal-title":"Br J Haematol"},{"key":"5775_CR27","doi-asserted-by":"crossref","unstructured":"Tembhare PR, Sriram H, Khanka T, Chatterjee G, Panda D et al (2020) Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. J Immunother Cancer 8","DOI":"10.1136\/jitc-2020-000630"},{"key":"5775_CR28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019000904","volume":"134","author":"F Vogiatzi","year":"2019","unstructured":"Vogiatzi F, Winterberg D, Lenk L, Buchmann S, Cario G et al (2019) Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood 134:713\u2013716","journal-title":"Blood"},{"key":"5775_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","volume":"34","author":"Y Ofran","year":"2020","unstructured":"Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D et al (2020) Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia. Leukemia 34:293\u2013295","journal-title":"Leukemia"},{"key":"5775_CR30","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K et al (2014) ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124:3738\u20133747","journal-title":"Blood"},{"key":"5775_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM et al (2020) Clinical experience with Venetoclax Combined with Chemotherapy for relapsed or refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20:212\u2013218","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5775_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00277-023-05083-y","volume":"102","author":"M Stanulla","year":"2023","unstructured":"Stanulla M, Schewe DM, Bornhauser B, Bourquin JP, Eckert C et al (2023) Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia. Ann Hematol 102:669\u2013672","journal-title":"Ann Hematol"},{"key":"5775_CR33","first-page":"9","volume":"136","author":"F Yang","year":"2020","unstructured":"Yang F, Li Z, Dong C, Lei Y, Geng Y et al (2020) Daratumumab and Venetoclax-Containing regimens in the management of Relapse after Allogeneic hematopoietic stem cell transplantation in hematological malignancies. Blood 136:9","journal-title":"Blood"},{"key":"5775_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s40364-021-00343-3","volume":"9","author":"S Voruz","year":"2021","unstructured":"Voruz S, Blum S, de Leval L, Schoumans J, Solly F, Spertini O (2021) Daratumumab and Venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed\/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript. Biomark Res 9:92","journal-title":"Biomark Res"},{"key":"5775_CR35","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1182\/bloodadvances.2022007364","volume":"6","author":"F Vogiatzi","year":"2022","unstructured":"Vogiatzi F, Heymann J, M\u00fcller K, Winterberg D, Drakul A et al (2022) Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis. Blood Adv 6:4847\u20134858","journal-title":"Blood Adv"},{"key":"5775_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.exphem.2017.04.002","volume":"51","author":"S Lepretre","year":"2017","unstructured":"Lepretre S, Graux C, Touzart A, Macintyre E, Boissel N (2017) Adult T-type lymphoblastic lymphoma: treatment advances and prognostic indicators. Exp Hematol 51:7\u201316","journal-title":"Exp Hematol"},{"key":"5775_CR37","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain N, Lamb AV, O\u2019Brien S, Ravandi F, Konopleva M et al (2016) Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood 127:1863\u20131869","journal-title":"Blood"},{"key":"5775_CR38","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1158\/1078-0432.CCR-22-2924","volume":"29","author":"W Chen","year":"2023","unstructured":"Chen W, Shi H, Liu Z, Yang F, Liu J et al (2023) Single-cell Transcriptomics reveals Immune reconstitution in patients with R\/R T-ALL\/LBL treated with donor-derived CD7 CAR-T therapy. Clin Cancer Res 29:1484\u20131495","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05775-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:06:49Z","timestamp":1722060409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5775"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05775-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board.The study was approved by the Ethics Committee at the Beijing Gobroad Boren Hospital in Beijing Informed Consent.Written informed consent was obtained from each patient. Clinical Trials Number: egistry and The Registration No. of the study\/trial: ChiCTR2200058095.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic statement"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}]}}